QuellTX
Ricardo Joseph has a solid scientific background with extensive work experience in the field. Ricardo started their career as an Associate Researcher at the University of Birmingham in 2009, where they worked until 2016. During their time there, they gained valuable research experience. Following that, they joined King's College London as an Associate Researcher for a year before transitioning to GammaDelta Therapeutics, where they held roles as an Associate Scientist and later a Process Development Scientist from 2017 to 2020. In 2020, Ricardo joined TCR² Therapeutics Inc. and worked as a Manufacturing Scientist before being promoted to Manufacturing Scientist II. Ricardo stayed with the company until 2021. Currently, Ricardo works as a Senior Process Development Scientist at Quell Therapeutics, where they began their tenure in late 2021. Throughout their career, Ricardo has demonstrated their expertise and commitment to scientific research and development.
Ricardo Joseph has a Bachelor of Science (BSc) degree in Developmental Biology and Embryology from UCL, as well as an MSc in Immunology from Imperial College London. Ricardo also attended the University of Birmingham, although their degree and field of study from that institution are not specified.
This person is not in the org chart
QuellTX
4 followers
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions.Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cellengineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.